Literature DB >> 7842192

Importance of total serum IgE for improvement in airways hyperresponsiveness with inhaled corticosteroids in asthma and chronic obstructive pulmonary disease. The Dutch CNSLD Study Group.

H A Kerstjens1, J P Schouten, P L Brand, D F Schoonbrood, P J Sterk, D S Postma.   

Abstract

Airways hyperresponsiveness is a hallmark of asthma, and many patients with COPD also demonstrate hyperresponsiveness. Inhaled corticosteroids improve hyperresponsiveness, but the extent of improvement may vary considerably between patients. This study was designed to determine which patient characteristics predict these differences in response. Patients with mild to moderately severe obstructive airways disease (asthma and COPD) were selected if PC20 < or = 8 mg/ml and FEV1 < 95% confidence interval of predicted normal. They were followed for 2.5 yr, during which one-third received inhaled corticosteroids. The independent influences of baseline FEV1/IVC, bronchodilator response, PC20, smoking habits, allergy, age, and sex on the improvement in airways hyperresponsiveness with inhaled corticosteroids were analyzed. Total serum IgE was taken as a parameter of allergy, next to specific IgE for house dust mite, skin tests, and blood eosinophils. Total serum IgE was found to be the most important and single independent predictor of change in PC20 with inhaled corticosteroids: patients with a higher IgE had a greater increase in PC20 when administered inhaled corticosteroids than those with lower IgE levels. Alternatively, patients with a higher IgE who did not receive corticosteroids had a decrease in PC20 compared with patients with a lower IgE. This effect was most prominent in asthma but was inconsistent in asthmatic bronchitis and COPD. The level of IgE cannot be used to predict the response to inhaled corticosteroids in individuals accurately. Total serum IgE is the single most important predictor of change in PC20 with and without inhaled corticosteroids.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7842192     DOI: 10.1164/ajrccm.151.2.7842192

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  9 in total

Review 1.  Beclomethasone for asthma in children: effects on linear growth.

Authors:  P J Sharek; D A Bergman
Journal:  Cochrane Database Syst Rev       Date:  2000

2.  Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease.

Authors:  Manisha Singh; Seung-Hyo Lee; Paul Porter; Chuang Xu; Ayako Ohno; Robert L Atmar; Stephen B Greenberg; Venkata Bandi; Jim Gern; Svetlana Amineva; Alex Aminev; Tim Skern; Pamela Smithwick; Sarah Perusich; Nadia Barrow; Luz Roberts; David B Corry; Farrah Kheradmand
Journal:  J Allergy Clin Immunol       Date:  2010-06       Impact factor: 10.793

Review 3.  Anticholinergic agents for chronic asthma in adults.

Authors:  M Westby; M Benson; P Gibson
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 4.  Which biomarkers are effective for identifying Th2-driven inflammation in asthma?

Authors:  Zuzana Diamant; Ellen Tufvesson; Leif Bjermer
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

5.  Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma.

Authors:  Jason E Knuffman; Christine A Sorkness; Robert F Lemanske; David T Mauger; Susan J Boehmer; Fernando D Martinez; Leonard B Bacharier; Robert C Strunk; Stanley J Szefler; Robert S Zeiger; Lynn M Taussig
Journal:  J Allergy Clin Immunol       Date:  2009-01-03       Impact factor: 10.793

Review 6.  Inhaled corticosteroids for stable chronic obstructive pulmonary disease.

Authors:  Ian A Yang; Melissa S Clarke; Esther H A Sim; Kwun M Fong
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

7.  Challenges and choices in the pharmacological treatment of non-severe pediatric asthma: A commentary for the practicing physician.

Authors:  Omer Kalayci; Hanan Abdelateef; César Fireth Pozo Beltrán; Zeinab A El-Sayed; René Maximiliano Gómez; Elham Hossny; Mário Morais-Almeida; Antonio Nieto; Wanda Phipatanakul; Paulo Pitrez; Gary Wk Wong; Paraskevi Xepapadaki; Nikolaos G Papadopoulos
Journal:  World Allergy Organ J       Date:  2019-10-03       Impact factor: 4.084

8.  Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity.

Authors:  D B Corry; H G Folkesson; M L Warnock; D J Erle; M A Matthay; J P Wiener-Kronish; R M Locksley
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

Review 9.  Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?

Authors:  Dirkje S Postma; Huib A M Kerstjens; Nick H T ten Hacken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-24       Impact factor: 3.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.